8701 Morristesse Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morristesse Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morristesse Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 6, 2021, Purisys, LLC, 1550 Olympic Drive, Atlanta, Georgia 30360–1602, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noroxymorphine</td>
<td>9668</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to use as reference standards for analytical and research purposes for their customers. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to import of the Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

William T. McDermott, Assistant Administrator.

[FR Doc. 2021–11070 Filed 5–25–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF LABOR

Drug Enforcement Administration

Import of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Almac Clinical Services Incorp. (ACSI) has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before June 25, 2021. Such persons may also file a written request for a hearing on the application on or before June 25, 2021.

ADDRESS: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morristesse Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morristesse Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morristesse Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morristesse Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on April 30, 2021, Almac Clinical Services Incorp, (ACSI) 25 Fretz Road, Souderton, Pennsylvania 18964, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td>I</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>9143</td>
<td>II</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>9150</td>
<td>II</td>
</tr>
<tr>
<td>Morphine</td>
<td>9330</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphine</td>
<td>9668</td>
<td>II</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td>II</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>9801</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import the listed finished dosage unit products controlled substances in dosage form to conduct clinical trials. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to import of the Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

William T. McDermott, Assistant Administrator.

[FR Doc. 2021–11069 Filed 5–25–21; 8:45 am]

BILLING CODE P

DEPARTMENT OF LABOR

Employment and Training Administration

Workforce Innovation and Opportunity Act; Native American Employment and Training Council

AGENCY: Employment and Training Administration, U.S. Department of Labor.

ACTION: Notice of meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act (FACA), and the Workforce Innovation and Opportunity Act (WIOA), notice is hereby given of the next meeting of the Native American Employment and Training Council (Council), as constituted under WIOA.

DATES: The meeting will begin at 12:00 p.m., (Eastern Daylight Time) on Tuesday, June 15, 2021, and continue until 4:30 p.m. The meeting will reconvene at 12:00 p.m., on Wednesday, June 16, 2021 and adjourn at 4:30 p.m. The period from 3:00 p.m., to 4:00 p.m., on June 16, 2021 is reserved for participation and comment by members of the public.

ADDRESS: The meeting will be held virtually on the Zoom.gov platform. To join the meeting use the following:

Dial in number: +1 (551) 285–1373.

SUPPLEMENTARY INFORMATION: Council members and members of the public are encouraged to logon to Zoom.gov early to allow for connection issues and troubleshooting.

Security Instructions: Meeting participants should use the link and dial in instructions provided in ADDRESSES. The meeting will be open to the public.

Members of the public not present may submit a written statement by Thursday, June 11, 2021, to be included in the record of the meeting. Statements are to be submitted to Athena R. Brown, Designated Federal Officer (DFO), U.S. Department of Labor at brown.athena@ dol.gov. Persons who need special accommodations should contact Suzie Casal at (703) 967–1829 or casal.suzie@dol.gov, at least two business days before the meeting. The formal agenda will focus on the following topics: (1) Update of National Congress of American Indians policy recommendations, (2) PY 2021/2022 training and technical assistance priorities, (3) update Indian and